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transfusion (17.9%) than either TF-TAVR (7.1%) or TA-TAVR (4.8%; p < 0.0001). Independent predictors of major BC
were the occurrence of major vascular complications and use of intraprocedural hemodynamic support among
TF-TAVR patients, severe procedural complications requiring conversion to open surgery among TA-TAVR patients,
and the presence of low hemoglobin at baseline among SAVR patients. Major BC was identiﬁed as the strongest
independent predictor of 1-year mortality among the full cohort. However, risk-adjusted analyses demonstrated
a signiﬁcant interaction between BC and treatment strategy with respect to mortality, suggesting that BC after SAVR
have a greater impact on prognosis than after TAVR.Conclusions Among high-risk aortic stenosis patients enrolled in the PARTNER I randomized trial, BC were more common after SAVR
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1101toward smaller device sizes, complications such as vascular
complications or major bleeding are expected to decrease
signiﬁcantly. SAVR, a well-established treatment for degen-
erative aortic valve disease, is associated with a non-negligible
risk of bleeding and transfusion of blood products (9).See page 1110
HR = hazard ratio
RBC = red blood cells
SAVR = surgical aortic valve
replacement
TA = transapical
TAVR = transcatheter aortic
valve replacement
TF = transfemoral
VARC = Valve Academic
Research ConsortiumHowever, there is a paucity of data (observational or
randomized) comparing the occurrence of bleeding events
among patients undergoing TAVR or SAVR. In this study,
we sought to better characterize and compare the incidence,
predictors, and impact of bleeding events on long-term
prognosis after SAVR and TAVR using data from the
multicenter, randomized PARTNER (Placement of Aortic
Transcatheter Valve) I trial.Methods
Study population. The design and initial results of the
randomized PARTNER trial (cohort B and cohort A) have
been published previously (5,6). Brieﬂy, the PARTNER trial
enrolled patients with severe symptomatic aortic stenosis.
Patients were divided into 2 cohorts: 1) those who were
considered to be candidates for surgery despite being at high
surgical risk, as deﬁned by a Society of Thoracic Surgeons
(STS) risk score of 10% or higher or by the presence of
coexisting conditions that would be associated with a 15% or
greater predicted risk of death by 30 days after surgery
(cohort A); and 2) those who were not considered to be
suitable candidates for surgery because they had coexisting
conditions that would be associated with a predicted prob-
ability of 50% or more of either death by 30 days after surgery
or a serious irreversible condition (cohort B). The current
analysis examines patients from cohort A only, in which
randomization to SAVR versus TAVR allowed for
comparison of similar populations.
Patients enrolled in cohort A were randomly assigned to
TAVR with the SAPIEN heart valve system (Edwards
Lifesciences, Irvine, California), using a transfemoral (TF)
approach if vascular access was suitable or a transapical
(TA) approach if not, or to conventional SAVR. The study
was approved by the institutional review board at each
participating site, and all patients provided written informed
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accepted October 22, 2013.Study endpoints. All BC were
deﬁned according to a modiﬁed
version of the Valve Academic
Research Consortium (VARC)
criteria as described in the PART-
NER trial protocol (5,6,10,11).
Bleeding events were classiﬁed as
either major or minor. Major BC
were deﬁned as a clear site of
bleeding that met any of the
following criteria: 1) bleeding that
caused death; 2) bleeding that
caused a new hospitalization or
prolonged hospitalization 24 h
due to treatment; 3) bleeding
that required pericardiocentesis
or open and/or endovascular procedure for repair or
hemostasis; 4) bleeding that caused permanent disability
(e.g., blindness, paralysis, hearing loss); and 5) bleeding that
required transfusion of >3 U of blood within a 24-h period.
Minor bleeding had to meet all of the following criteria:
1) bleeding event that did not meet criteria for major
bleeding; 2) clear site for bleeding; and 3) loss of hemo-
globin >3 g/dl or loss of hematocrit >9%. Adjustment for
transfusions was included at 1 g/dl or 3% for each unit of
blood.
The 30-day and 1-year frequency of all-cause mortality,
cardiovascular mortality, stroke, major vascular complication,
myocardial infarction, and acute kidney injury were reported
according to initial VARC deﬁnitions (10) or according to
a modiﬁed version of the VARC criteria as described in the
PARTNER trial protocol. An independent clinical events
committee adjudicated all adverse events. Further extensive
review of the source documents was performed by 2 inves-
tigators to better characterize the cause of bleeding events
(P.G.) and to subcategorize the cause of death (L.G.S.).
Independent core laboratories analyzed all echocardiograms
and electrocardiograms. All data were sent for analysis to an
independent academic biostatistics group.
Statistical analysis. Continuous variables are summarized
as mean  SD or median (quartile [Q1, Q3]), as appropriate,
and were compared using the Student t test or Mann-
Whitney rank-sum test accordingly. Categorical variables
were compared by the chi-square or the Fisher exact tests.
Survival curves for time-to-event variables were constructed on
the basis of all available follow-up data with the use of Kaplan-
Meier estimates, and comparisons were performed using the
log-rank test.
Multivariable logistic regression was performed to iden-
tify independent predictors of 30-day major BC for each
treatment strategy (a ¼ 0.05). The multivariable model
was built by stepwise selection, with candidate variables
being selected if of clinical interest and/or satisfying the
entry criterion of p < 0.10 in the univariate analysis.
Variables included in the model were carefully selected to
avoid overﬁtting. To assess the association between major
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1102BC and 1-year rate of all-cause mortality, Cox multivariable
regression analyses were performed, with variable selection
performed as previously described. A second Cox multi-
variable regression analyses were performed, with moderate
to severe paravalvular leak (at discharge or inside 7 days) and
stroke forced into the model given their clinical relevance
(Online Appendix). A 2-sided alpha level of 0.05 was used
for all superiority testing. We also tested for an interaction
between the type of procedure (TAVR vs. SAVR and TF-
TAVR vs. SAVR). The association between major bleeding
and mortality was assessed, and its impact on 1-year
mortality was appraised. Hazard ratios (HRs) were
adjusted for independent predictors of 1-year mortality
identiﬁed in the previous multivariable analysis. All statis-
tical analyses were performed with the use of SAS software,
version 9.2 (SAS Institute, Cary, North Carolina).
Results
Patients and baseline characteristics. Among the 699
patients enrolled in the PARTNER trial cohort A (high risk
but operable), 313 patients were actually treated by SAVR,
240 patients were treated by the TAVR-TF approach, and
104 patients were treated by the TAVR-TA approach, for
a total of 657 patients included in the current analysis. Major
BC were signiﬁcantly more frequent in the SAVR group (71
of 313 [22.7%]) compared with patients in the TAVR-TF
group (27 of 240 [11.3%]) and the TAVR-TA group (9
of 104 [8.8%]; p < 0.0001) (Fig. 1).
Baseline and procedural characteristics of patients strati-
ﬁed according to the occurrence of major BC within 30 days
and by treatment strategy are shown in Tables 1 and 2.
Patients with major BC more frequently had diabetes
requiring insulin (TF-TAVR), had higher international
normalized ratio at baseline (TAVR-TA and SAVR), hadFigure 1
30-Day Major Bleeding Rates According
to Treatment Strategy
Major bleeding event rates at 30 days were signiﬁcantly more frequent with
surgical aortic valve replacement (SAVR) than with transfemoral (TF) or transapical
(TA) transcatheter aortic valve replacement (TAVR).lower hemoglobin at baseline (SAVR), and were less likely
to have signiﬁcant coronary disease at baseline (TAVR-TA).
During the procedure, major BC were associated with
higher rates of migration or embolization of the prosthesis,
use of hemodynamic support devices, conversion to open
heart surgery, and use of higher doses of heparin (TAVR-
TF and TAVR-TA), resulting in longer procedure times
(TAVR-TF). Among TAVR-TA patients, failure to suc-
cessfully implant a transcatheter heart valve was also asso-
ciated with major BC. Smaller valve size, longer sternal
incisions, and longer procedural times were characteristics
associated with major BC among SAVR-treated patients.
Interestingly, post-procedure length of stay was not pro-
longed in association with major BC in either of the TAVR
groups, but was signiﬁcantly prolonged in the SAVR group
(11 days vs. 8 days; p ¼ 0.005). Speciﬁc causes of major BC
stratiﬁed by treatment strategy are shown in Online Table 1.
Clinical outcomes. At 30 days, SAVR was associated with
a signiﬁcantly higher rate of transfusions compared with
either TAVR-TF or -TA (Fig. 2). Among patients receiving
transfusions during the index hospitalization, the propor-
tion of patients receiving 4 transfusions was 69.6% in
the SAVR group (median: 7.0 [1st, 3rd quartiles: 3.0,
9.0]), 66.7% in the TA-TAVR group (median: 4.0
[1st, 3rd quartiles: 1.0, 7.0]), and 40.5% in the TF-TAVR
group (median: 3.5 [1st, 3rd quartiles: 2.0, 5.0]; p for
trend ¼ 0.0002).
Clinical outcomes of patients stratiﬁed by major BC versus
nomajor BC for each treatment strategy are shown in Table 3.
The occurrence of major BC after TAVR-TF was associated
with signiﬁcantly higher 30-day rates of major vascular
complications and with a trend toward a higher rate of renal
failure requiring dialysis, but no signiﬁcant increase in all-
cause or cardiovascular mortality. The occurrence of major
BC after TAVR-TA was associated with a non-signiﬁcant
trend of higher 30-day rates of major vascular complications
and cardiovascular mortality. Within the SAVR group, the
occurrence of major BC was associated with signiﬁcantly
higher 30-day rates of acute kidney failure requiring dialysis
and major vascular complications (such as aortic perforation
and aortic dissection), with signiﬁcantly higher rates of
30-day and 1-year all-cause and cardiac mortality.
Impact of major bleeding on 1-year mortality according
to procedure. The impact of 30-day major BC on 1-year
mortality is shown in Figure 3. The occurrence of major
BC compared with no major BC was associated with an
increased rate of 1-year mortality among the total population
(Fig. 3A). When stratiﬁed by treatment group, major BC
were associated with an increased 1-year mortality rate
among SAVR-treated patients (Fig. 3B). However, among
patients treated by TAVR, there was no difference in 1-year
mortality between patients who experienced major BC
compared with no major BC regardless of the access site
(Figs. 3C to 3E). Speciﬁc causes of death among patients
with major BC experiencing death, stratiﬁed by treatment
strategy, are shown as supplementary data (Online Table 2).
Table 1 Baseline Characteristics of Patients Undergoing TAVR or SAVR According to Occurrence of Major Bleeding Inside 30 Days
Variables
TAVR-TF TAVR-TA SAVR
Major Bleeding
(n ¼ 27)
No Major Bleeding
(n ¼ 213) p Value
Major Bleeding
(n ¼ 9)
No Major Bleeding
(n ¼ 95) p Value
Major Bleeding
(n ¼ 71)
No Major Bleeding
(n ¼ 242) p Value
Age, yrs 83.60  6.62 83.93  6.80 0.84 84.3  6.09 82.8  7.08 0.49 83.7  6.88 84.6  6.17 0.48
Female 12/27 (44.4) 83/213 (39.0) 0.58 4/9 (44.4) 47/95 (49.5) 1.00 30/71 (42.3) 104/242 (43.0) 0.91
BMI, kg/m2 26.92  4.87 27.56  7.09 0.81 29.63  10.54 27.14  7.12 0.58 26.05  5.15 27.01  5.87 0.21
STS risk score 12.19  3.95 11.79  3.12 0.39 10.9  1.56 11.8  3.77 0.91 11.3  3.21 11.8  3.41 0.07
Logistic EuroSCORE 25.12  16.02 29.65  16.75 0.12 25.88  16.02 30.27  16.08 0.35 29.97  15.75 29.00  14.97 0.59
Diabetes mellitus 13/27 (48.1) 90/213 (42.3) 0.56 3/9 (33.3) 39/95 (41.1) 0.74 29/71 (40.8) 101/242 (41.7) 0.89
Insulin 4/13 (30.8) 7/90 (7.8) 0.03 0/3 (0.0) 0/39 (0.0) d 1/29 (3.4) 10/101 (9.9) 0.45
CHF 26/27 (96.3) 208/213 (97.7) 0.52 9/9 (100.0) 94/95 (98.9) 1.00 71/71 (100.0) 237/241 (98.3) 0.58
NYHA functional
class III
11/27 (40.7) 91/213 (42.7) 0.84 4/9 (44.4) 38/95 (40.0) 1.00 32/71 (45.1) 102/242 (42.1) 0.66
NYHA functional
class IV
13/27 (48.1) 113/213 (53.1) 0.63 3/9 (33.3) 51/95 (53.7) 0.31 36/71 (50.7) 127/242 (52.5) 0.79
CAD 19/27 (70.4) 162/213 (76.1) 0.52 4/9 (44.4) 73/95 (76.8) 0.05 58/71 (81.7) 183/242 (75.6) 0.29
Prior PCI 8/26 (30.8) 74/212 (34.9) 0.68 2/9 (22.2) 31/95 (32.6) 0.72 27/71 (38.0) 74/241 (30.7) 0.25
Prior CABG 9/27 (33.3) 88/213 (41.3) 0.43 3/9 (33.3) 48/95 (50.5) 0.49 36/71 (50.7) 104/242 (43.0) 0.25
CVD 8/26 (30.8) 48/201 (23.9) 0.44 2/9 (22.2) 38/87 (43.7) 0.30 18/70 (25.7) 61/222 (27.5) 0.77
PVD 13/27 (48.1) 70/211 (33.2) 0.12 6/9 (66.7) 59/94 (62.8) 1.00 28/71 (39.4) 104/236 (44.1) 0.49
Pulmonary HTN 12/27 (44.4) 105/213 (49.3) 0.63 7/9 (77.8) 48/95 (50.5) 0.17 29/71 (40.8) 121/242 (50.0) 0.17
Permanent pacemaker 6/27 (22.2) 42/213 (19.7) 0.76 1/9 (11.1) 20/95 (21.1) 0.68 19/71 (26.8) 51/242 (21.1) 0.31
COPD 12/27 (44.4) 92/213 (43.2) 0.90 2/5 (40.0) 42/59 (71.2) 0.17 27/47 (57.4) 106/156 (67.9) 0.18
Oxygen dependent 2/27 (7.4) 19/213 (8.9) 1.00 0/2 (0.0) 7/42 (16.7) 1.00 10/27 (37.0) 21/105 (20.0) 0.06
LVEF, % 55.57  15.24 50.47  14.61 0.20 55.53  9.41 53.07  13.40 0.67 53.68  11.28 53.74  12.83 0.89
AV area, cm2 0.72  0.20 0.65  0.19 0.09 0.71  0.23 0.65  0.20 0.61 0.63  0.19 0.64  0.19 0.37
Mean AV gradient,
mm Hg
44.59  14.55 42.92  14.83 0.72 38.66  6.99 41.89  14.29 0.57 42.60  15.39 43.65  14.00 0.48
WBC 103/ml 8.54  4.37 10.61  53.14 0.16 6.81  1.92 7.42  2.28 0.61 7.23  2.17 7.19  2.41 0.62
Hemoglobin, g/dl 11.37  1.25 11.76  2.08 0.26 11.39  0.68 11.87  1.74 0.51 11.38  1.43 11.94  1.78 0.01
Platelets, cells/mm3 217.0 (147.0–242.0) 201.5 (156.5–283.0) 0.85 207.0 (203.0–244.0) 198.0 (163.0–258.0) 0.23 199.5 (161.0–260.0) 210.00 (159.0–292.0) 0.14
INR 1.28  0.69 1.25  0.79 0.45 1.40  0.44 1.14  0.25 0.01 1.27  1.25 1.22  0.67 0.03
Cr clearance, ml/min 0.88  0.33 0.80  0.40 0.28 0.78  0.44 0.81  0.40 0.82 0.83  0.38 0.81  0.39 0.75
Values are mean  SD, n/total N (%), or median (interquartile range).
AV ¼ aortic valve; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft surgery; CAD ¼ coronary artery disease; CHF ¼ cardiac heart failure; COPD ¼ chronic obstructive pulmonary disease; Cr ¼ creatinine; CVD ¼ cerebrovascular disease; EuroSCORE ¼ European
System for Cardiac Operative Risk Evaluation; HTN ¼ hypertension; INR ¼ international normalized ratio; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; PVD ¼ peripheral vascular disease;
SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgeons; TA ¼ transapical; TAVR ¼ transcatheter aortic valve replacement; TF ¼ transfemoral; WBC ¼ white blood cells.
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Table 2 Procedural Characteristics of Patients According to Occurrence of Major Bleeding Inside 30 Days
Variables
TAVR-TF TAVR-TA
Major Bleeding
(n ¼ 27)
No Major Bleeding
(n ¼ 213) p Value
Major Bleeding
(n ¼ 9)
No Major Bleeding
(n ¼ 95) p Value
Valve size, mm
23 12/27 (44.4) 97/206 (47.1) 0.80 5/9 (55.6) 47/92 (51.1) 1.00
26 15/27 (55.6) 109/206 (52.9) 0.80 4/9 (44.4) 45/92 (48.9) 1.00
Study valve successfully implanted 26/27 (96.3) 202/206 (98.1) 0.46 6/8 (75.0) 90/92 (97.8) 0.03
Migration or embolization 3/23 (13.0) 1/172 (0.6) 0.005 2/5 (40.0) 1/74 (1.4) 0.009
Hemodynamic support, CPB or IABP 5/27 (18.5) 3/207 (1.4) 0.0006 4/9 (44.4) 9/93 (9.7) 0.01
Conversion to open heart surgery 4/27 (14.8) 2/207 (1.0) 0.002 2/9 (22.2) 1/93 (1.1) 0.02
Artery closure
Surgical cutdown 18/27 (66.7) 150/207 (72.5) 0.53 d d d
Closure device 10/27 (37.0) 55/207 (26.6) 0.25 d d d
Total procedure time, min 143.00 (111.00–219.00) 114.00 (90.00–154.00) 0.02 122.00 (60.00–267.00) 95.00 (68.00–120.00) 0.42
Heparin administrated, U 9,000.00 (6,500.00–10,000.00) 7,000.00 (5,000.00–10,000.00) 0.04 10,000.0 (10,000.0–30,000.0) 8,000.0 (5,000.0–10,000.0) 0.005
Days in hospital post-procedure 6.00 (4.00–8.00) 5.00 (4.00–7.00) 0.34 7.50 (7.00–8.00) 8.00 (7.00–9.00) 0.80
SAVR
Variables
Major Bleeding
(n ¼ 71)
No Major Bleeding
(n ¼ 242) p Value
Valve size, mm 21.00 (21.00–23.00) 23.00 (21.00–23.00) 0.04
19 12/71 (16.9) 25/241 (10.4) 0.13
21 30/71 (42.3) 94/241 (39.0) 0.62
23 23/71 (32.4) 86/241 (35.7) 0.61
25 5/71 (7.0) 32/241 (13.3) 0.15
27 0/71 (0.0) 3/241 (1.2) 1.00
Other 1/71 (1.4) 1/241 (0.4) 0.40
Total procedure time, min 351.5 (265.0–461.0) 311.0 (260.0–364.0) 0.01
Total aortic cross-clamp time, min 66.0 (54.0–87.0) 67.0 (57.0–82.0) 0.97
Pump time, min 97.5 (81.5–145.0) 94.0 (79.0–117.0) 0.12
Length of skin incision, mm 19.0 (12.0–24.0) 14.5 (10.0–21.0) 0.04
Heparin administered, U 25,000.0 (20,000.0–32,000.0) 29,000.0 (21,000.0–35,000.0) 0.34
Days in hospital post-procedure 11.0 (8.5–16.5) 8.0 (7.0–10.0) 0.005
Values are n/total N (%) median (interquartile range).
CPB ¼ cardiopulmonary bypass; IABP ¼ intra-aortic balloon pump; other abbreviations as in Table 1.
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Figure 2
Patients Receiving at Least 1 Transfusion Within
30 Days Per Treatment Strategy
Transfusion rates at 30 days were signiﬁcantly higher with SAVR than with
TF- or TA-TAVR. Abbreviations as in Figure 1.
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1105Predictors of bleeding and mortality. Variables associated
with major BC are summarized in Table 4. After multi-
variable analysis, major vascular complications and severe
intraprocedural complications leading to the use of hemo-
dynamic support were identiﬁed as the strongest indepen-
dent predictors of major BC in the TAVR-TF group.
Similarly, the need for conversion to open surgery was
the most signiﬁcant predictor of bleeding events in the
TA-TAVR group. For patients who underwent SAVR, low
baseline hemoglobin was the only independent predictor of
major BC within 30 days.
Independent predictors of 1-year mortality among the full
cohort are summarized in Table 5. Among pre-procedure
variables, higher Society of Thoracic Surgeons risk score,
lower body mass index, oxygen-dependent chronic obstruc-
tive pulmonary disease, and renal dysfunction emerged as
independent predictors of mortality. After adjustment for
these factors, major bleeding within 30 days was strongly and
independently associated with mortality (adjusted HR: 2.49;
95% conﬁdence interval [CI]: 1.85 to 3.37; p < 0.001). A
second Cox regression analysis was performed with moderate
to severe PVL and stroke forced into the model, with major
bleeding remaining the strongest predictor of 1-year
mortality (adjusted HR: 2.36; 95% CI: 1.68 to 3.31;
p < 0.001) (Online Table 3). Interaction testing demon-
strated that this association differed signiﬁcantly according to
the type of procedure (TAVR vs. SAVR, p value for
interaction ¼ 0.046). For patients treated with SAVR, major
BC tended to be associated with increased 1-year mortality
(adjusted HR: 1.95; 95% CI: 0.95 to 4.01; p ¼ 0.07),
whereas no such association was apparent for patients treated
by TAVR (adjusted HR: 0.86; 95% CI: 0.60 to 1.25;
p ¼ 0.43) (Fig. 4A). Similarly, interaction testing restricted
to TF-TAVR population showed similar results, with major
BC after SAVR being associated with increased 1-yearmortality, whereas major BC after TF-TAVR were not
(Fig. 4B).
Discussion
The current report is the largest randomized study to
speciﬁcally evaluate and compare the incidence, predictors,
and impact of major BC on long-term prognosis after
different treatment strategies for patients with severe aortic
stenosis. The main results of the present study are as
follows: 1) among a population of high-risk but operable
patients, BC and transfusions were more frequent among
SAVR-treated patients than among TAVR-treated patients
using ﬁrst-generation devices; 2) the occurrence of major
BC after TAVR was associated with vascular complications
and important procedural complications, whereas baseline
hemoglobin was the main predictor of BC after SAVR; and
3) the impact of major BC on 1-year mortality differed
according to treatment strategy, with SAVR being associ-
ated with more severe and lethal bleeding than TAVR.
Prior studies have reported high rates of bleeding after
TAVR (12,13). Life-threatening and major bleeding after
TAVR, deﬁned by VARC criteria (10,11), occurred in
approximately 15% and 20% of TAVR procedures, respec-
tively, in the early literature (12). Tchetche et al. (13)
recently reported similar rates (13.9% and 20.9%, respec-
tively), with 38.9% of patients undergoing TAVR receiving
at least 1 transfusion. Conversely, Tamburino et al. (14)
reported lower bleeding event rates, with 30-day rates of
life-threatening bleeding of 5.5% and 9.0% after TAVR and
SAVR, respectively. More recently, Toggweiler et al. (7)
showed that with careful patient selection and advanced
interventional techniques, marked reductions in bleeding
(and vascular) complications could be achieved, with rates
as low as 1% at 30 days after TF-TAVR. However, the
heterogeneity of these populations, the lack of independent
adjudication of events, and the absence of direct comparison
with a surgical cohort of similar risk represent important
limitations to these reports.
The current report, derived from the randomized
PARTNER trial experience, shows that rates of major BC
and transfusions were 2 to 3 times more frequent in the
SAVR group than in the TAVR group. This ﬁnding is not
particularly surprising, given the more invasive nature of
surgical AVR as well as the well-documented coagulopathy
that occurs after cardiopulmonary bypass. Conversely, the
apparent differential prognostic impact of major BC among
patients treated with TAVR or SAVR was unexpected. One
possible explanation for this ﬁnding is that BC after SAVR
appear to be more severe, leading to transfusion of a higher
number of red blood cell (RBC) units, acute renal failure
needing dialysis, reoperation, and consequently, a higher
death rate. Taking into consideration that the PARTNER
trial represented the earliest TAVR experience of all
enrolling centers, that it used the larger ﬁrst-generation
TAVR delivery system (22- and 24-F), and that SAVR
Table 3 30-Day and 1-Year Adverse Event Rates According to Occurrence of Major Bleeding Inside 30 Days
Variables
TAVR-TF TAVR-TA SAVR
Major
Bleeding
(n ¼ 27)
No Major
Bleeding
(n ¼ 213) p Value
Major
Bleeding
(n ¼ 9)
No Major
Bleeding
(n ¼ 95) p Value
Major
Bleeding
(n ¼ 71)
No Major
Bleeding
(n ¼ 242) p Value
30-day events
Death
From any cause 3.7 (1) 3.8 (8) 1.00 11.1 (1) 8.4 (8) 0.76 21.2 (15) 4.1 (10) <0.0001
From CV cause 3.7 (1) 3.3 (7) 0.90 11.1 (1) 4.2 (4) 0.35 7.5 (5) 1.7 (4) 0.01
Repeat hospitalization 0.0 (0) 6.2 (13) 0.20 0.0 (0) 5.5 (5) 0.50 6.7 (4) 6.0 (14) 0.88
Stroke or TIA 3.7 (1) 4.7 (10) 0.82 0.0 (0) 7.6 (7) 0.43 4.4 (3) 2.1 (5) 0.28
TIA 3.7 (1) 1.0 (2) 0.22 0.0 (0) 0.0 (0) d 0.0 (0) 0.4 (1) 0.60
Stroke 0.0 (0) 3.8 (8) 0.31 0.0 (0) 7.6 (7) 0.43 4.4 (3) 2.1 (5) 0.28
Major 0.0 (0) 2.8 (6) 0.38 0.0 (0) 6.5 (6) 0.46 4.4 (3) 1.7 (4) 0.17
Minor 0.0 (0) 0.9 (2) 0.61 0.0 (0) 1.1 (1) 0.77 0.0 (0) 0.4 (1) 0.60
Myocardial infarction 0.0 (0) 0.0 (0) d 0.0 (0) 0.0 (0) d 1.4 (1) 0.0 (0) 0.06
Vascular complications 67.4 (18) 18.3 (39) <0.0001 11.1 (1) 4.2 (4) 0.34 11.3 (8) 2.5 (6) 0.002
Major 67.4 (18) 7.0 (15) <0.0001 11.1 (1) 3.2 (3) 0.22 11.3 (8) 1.7 (4) 0.0002
Renal failure, dialysis required 7.6 (2) 2.8 (6) 0.21 0.0 (0) 5.5 (5) 0.50 8.9 (6) 3.3 (8) 0.05
Dialysis >30 days 0.0 (0) 0.5 (1) 0.72 0.0 (0) 1.1 (1) 0.77 1.5 (1) 2.1 (5) 0.79
PVL moderate-severe* 8.7 (2) 8.1 (16) 1.00 0.0 (0) 5.7 (5) 1.00 0.0 (0) 0.5 (1) 1.00
1-year events
Death
From any cause 22.4 (6) 21.2 (45) 0.81 44.4 (4) 27.6 (26) 0.27 44.2 (31) 19.7 (47) <0.0001
From CV cause 12.1 (3) 8.0 (16) 0.48 11.1 (1) 8.9 (8) 0.76 12.7 (8) 6.2 (14) 0.04
Repeat hospitalization 23.1 (5) 17.0 (34) 0.78 25.0 (2) 15.8 (13) 0.48 17.7 (9) 16.4 (36) 0.88
Stroke or TIA 3.7 (1) 6.4 (13) 0.63 0.0 (0) 15.7 (13) 0.28 4.4 (3) 4.1 (9) 0.66
TIA 3.7 (1) 2.1 (4) 0.51 0.0 (0) 4.0 (3) 0.62 0.0 (0) 1.9 (4) 0.34
Stroke 0.0 (0) 4.3 (9) 0.28 0.0 (0) 11.7 (10) 0.34 4.4 (3) 2.6 (6) 0.36
Major 0.0 (0) 3.4 (7) 0.35 0.0 (0) 10.6 (9) 0.37 4.4 (3) 2.2 (5) 0.25
Minor 0.0 (0) 0.9 (2) 0.61 0.0 (0) 1.1 (1) 0.77 0.0 (0) 0.4 (1) 0.60
Myocardial infarction 0.0 (0) 0.0 (0) d 0.0 (0) 0.0 (0) d 1.4 (1) 0.0 (0) 0.06
Values are % (n). *At discharge or inside 7 days of the procedure as evaluated by echocardiogram.
CV ¼ cardiovascular; PVL ¼ paravalvular leak; TIA ¼ transient ischemic attack; other abbreviations as in Table 1.
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1106was performed by the most experienced and high-volume
surgeons, upcoming studies using smaller TAVR devices,
more experienced operators, and lower-risk populations
(8) may potentially increase the magnitude of beneﬁt of
TAVR over SAVR regarding rates of transfusion and
bleeding complications.
In the current report, the occurrence of major BC did not
seem to impact long-term prognosis in patients treated by
TF- or TA-TAVR. Conversely, the 30-day mortality rate
among patients undergoing SAVR and experiencing major
bleeding was high compared with TA- or TF-TAVR
(21.2%, 11.1%, and 3.7%, respectively), potentially under-
lining the severity of the initial bleeding events in the
surgical cohort.
Predictors of BC and RBC transfusions have been iden-
tiﬁed by several groups. Among them, vascular complica-
tions, major intraprocedural complications, female sex,
and baseline anemia have been most frequently reported
(13,15,16). Not surprisingly, in our cohort, major vascular
complications were present in approximately two-thirds of
patients who had BC in the TF-TAVR population, but in
a lower proportion of patients who underwent TA-TAVRor SAVR. These results have been previously demon-
strated by several investigators who have reported that the
need for transfusion after major vascular complications, es-
pecially in the early TAVR experience, varied between
40.7% and 78.0% (13,17–19). Catastrophic events, such as
migration and embolization of prosthesis, requirement of
hemodynamic/cardiopulmonary support, and the need to
convert to open surgery also explained some of the major
bleeding events after TAVR. However, the occurrence of
such dramatic complications is expected to decrease with
smaller devices and more experienced operators. Reasons for
transfusion after SAVR remain difﬁcult to deﬁne. The only
identiﬁable predictor of major bleeding after SAVR in the
current report was the presence of baseline anemia. Paired
with procedural blood loss and compensated by equivalent
blood transfusion, these 2 factors potentially remain the
main determinant of major bleeding events after SAVR.
Strategies to better capture, characterize, and prevent these
blood losses/transfusions after SAVR are warranted.
Several previous studies have established the deleterious
effect of RBC transfusions after a cardiovascular procedure
(9,15,20). Murphy et al. (9) reported that the short- and
Figure 3 Kaplan-Meier Curves Showing Cumulative Death Rates Through 1 Year
Comparison of the cumulative death rate through 1 year between patients with 30-day major bleeding (red lines) and with no 30-day major bleeding (blue lines), according to
procedure performed: (A) among the complete population; (B) among SAVR patients; (C) among both TF- and TA-TAVR patients; (D) among TA-TAVR patients; and (E) among
TF-TAVR patients. CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Figure 1.
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Table 4
Independent Clinical Predictors of Major Bleeding
Events According to Treatment Strategy
Predictors Adjusted HR (95% CI) p Value
TAVR-TF
Major vascular complications 11.64 (6.83–19.87) <0.0001
Use of intraprocedural hemodynamic
support
2.56 (1.18–5.56) 0.02
TAVR-TA
Conversion to open surgery 58.49 (6.82–502.0) 0.0002
Coronary disease at baseline 0.14 (0.03–0.73) 0.02
SAVR
Baseline hemoglobin 0.84 (0.72–0.98) 0.03
Candidate variables were female sex, insulin-dependent diabetes mellitus, baseline hemoglobin,
use of intraprocedural hemodynamic support, major vascular complications, migration or emboli-
zation of prosthesis, and conversion to open surgery for the TAVR-TF model; conversion to open
surgery, migration or embolization of prosthesis, and coronary disease at baseline for the TAVR-TA
model; and female sex, body mass index, baseline hemoglobin, international normalized ratio at
baseline, valve size, and oxygen-dependent chronic obstructive pulmonary disease for the SAVR
model.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
Figure 4
Adjusted Interaction Between Treatment Strategy
and 30-Day Major Bleeding and Impact on
1-Year Mortality
(A) Adjusted interaction between TAVR (TA and TF combined), versus SAVR, and
major bleeding at 30 days and its impact on 1-year mortality. (B) Adjusted inter-
action between TF-TAVR versus SAVR and major bleeding at 30 days and its impact
on 1-year mortality. A signiﬁcant interaction exists between the type of treatment
(TAVR or TF-TAVR vs. SAVR) and bleeding events at 30 days, and modulated the
impact of major bleeding on 1-year mortality. Bleeding events occurring in the TAVR
group, and speciﬁcally in the TF-TAVR group, have a signiﬁcantly less important
impact on 1-year mortality compared with bleeding events occurring among SAVR
patients, suggesting that bleeding events were less severe and potentially more
easily managed among TAVR (and TF-TAVR) patients compared with SAVR
patients. Adjusted for body mass index, Society of Thoracic Surgeons (STS) risk
score, renal disease at baseline, and chronic obstructive pulmonary disease
oxygen dependent. Abbreviations as in Figures 1 and 3.
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1108long-term risk of infection and ischemic events, length of
stay, and hospital cost increased proportionately with the
number of transfusions received after heart surgery. In the
current report, transfusion of RBC units were almost 4 and
3 times more frequent among SAVR patients compared
with operable TA- and TF-TAVR patients. These ﬁndings
are in line with a recently published report showing that
SAVR patients received a mean of 2.5 RBC units after
surgery compared with 0.5 after TAVR. Approximately 30%
of patients in the SAVR arm received 4 RBC units
compared with <4% for TAVR patients (21). Of note, the
signiﬁcantly higher number of transfusions evidenced in our
report for both the TAVR and SAVR cohort may be
explained not only by the higher-risk population treated, but
also by a more assiduous capture and reporting of all adverse
events in the context of a well-conducted randomized trial.
A recent study, published by Nuis et al. (15), demon-
strated the relationship between RBC units transfused and
the occurrence of acute kidney injury after TAVR. These
ﬁndings are consistent with our observation of higher rates
of acute renal failure requiring dialysis after SAVR compared
with after TAVR. These reports, as well as our study,
underline the close relationship among the severity of theTable 5
Independent Predictors of 1-Year Mortality Among
the Total Population
Predictors Adjusted HR (95% CI) p Value
Major bleeding at 30 days 2.49 (1.85–3.37) <0.0001
STS risk score 1.07 (1.03–1.10) <0.0001
Body mass index 0.96 (0.94–0.98) 0.001
Oxygen-dependent COPD 1.65 (1.13–2.41) 0.01
Baseline renal disease 1.31 (0.95–1.80) 0.10
Candidate variables for the model were age, female sex, body mass index, Society of Thoracic
Surgeons risk score, prior coronary artery bypass graft surgery, permanent pacemaker, renal
disease, malignant tumors, liver disease, oxygen-dependent chronic obstructive pulmonary disease,
left ventricular ejection fraction, baseline hemoglobin, baseline platelet; and major bleeding at 30
days (as time-dependent covariable).
Abbreviations as in Tables 1 and 4.initial bleeding event, the use of exogenous blood product,
and impact on mid-term and long-term outcomes, and the
need to prevent and decrease unnecessary post-procedural
RBC transfusions.
Study limitations. The PARTNER trial was performed
using ﬁrst-generation devices (large 22- and 24-F intro-
ducer sheath diameter for TF approaches and 29-F for TA
access) with operators and sites at the beginning of the
learning curve. Taking into account the ongoing evolution
toward lower-proﬁle TAVR devices, it is likely that even
greater differences between TAVR and SAVR in rates of
BC and transfusions might be seen in the future. Whereas
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by enrolling sites and adjudicated by an independent
committee, speciﬁc causes of bleeding (i.e., gastrointestinal
bleed) and reasons for transfusions were not systematically
documented. Baseline anemia was frequent in both groups,
and the exact etiology, although most likely multifactorial
and less likely to have precluded enrollment, is unknown.
The current report used a modiﬁed version of VARC-1
(10) and -2 (11) criteria. Although the use of VARC-2
criteria to report adverse events is strongly recommended
in any TAVR study, those criteria were not available at the
time of the initiation of the PARTNER IA trial. However,
the strong relationship between major bleeding events,
death, and treatment strategy is less likely to have been
affected. Access and closure were performed by surgical
cut-down in approximately 70% of patients and were fully
percutaneous in approximately 30% of PARTNER trial
cohort A patients (19). The severity and impact of bleed-
ing in the context where TF-TAVR procedure would
be performed fully percutaneously is still to be deter-
mined. Finally, although we adjusted for imbalances in
a number of important covariates, potential unmeasured
confounders may still be present. The results of this
observational post-hoc analysis should therefore be con-
sidered hypothesis generating.
Conclusions
Major BC were frequent after SAVR and TAVR using ﬁrst-
generation devices. However, among a cohort of patients
with similar risk proﬁles, major BC and the need for
transfusions were signiﬁcantly higher after SAVR than after
TAVR. In addition to their greater frequency, the adverse
prognostic impact of major BC was substantial among
patients treated with SAVR, but negligible among patients
receiving TAVR.
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